WPC Banner  
2010 Archived Content

IMG Web Header 

Day 1  |  Day 2 |  Download Brochure 

Recommended Short Courses*

Monday, June 14
9:00 am – 12:00 pm(SC1) Reactive Metabolites in Drug Discovery and Development-A Critical Examination of the Issues

2:00 pm – 5:00 pm(SC5) Dealing with the Blood-Brain Barrier 





12:30 pm Registration

KEYNOTE SESSIONin vivo Imaging—Where is it Having
the Biggest Impact in Drug Development?

1:55 Chairperson's Opening Remarks

Susanta Sarkar, Ph.D., Director, Clinical Imaging, Medicines Development, Oncology R&D, GlaxoSmithKline

2:00 Molecular Imaging Approaches: How can it Help Drug Discovery and Development?

Susanta Sarkar, Ph.D., Director, Clinical Imaging, Medicines Development, Oncology R&D, GlaxoSmithKline

It is critical to develop technologies that reduce attrition rates to improve the efficiency of the overall drug development process. This talk will discuss how the successful integration of molecular imaging approaches from bench to bedside would not only streamline drug development process but also allow for new opportunities in treatment management of targeted therapies including patient selection, dose optimization and optimal drug regimen.

2:30 Platform Imaging Biomakers—Applications across Pre-Clinical Drug Discovery with a Focus on Neuroscience, Oncology, Cardiovascular and Future Horizons

Thomas BocanThomas Bocan, Ph.D., Senior Director & Head, BioImaging Center, Pfizer Global Research & Development, Pfizer, Inc.

Imaging biomarkers allow for the pre-clinical and clinical assessment of proof of mechanism of novel drug candidates. With the development of novel PET tracers, imaging reagents and MR approaches, opportunities exist to broaden application to evolving tissue regeneration and stem cell approaches. Application of platform tools across numerous pharmacologic approaches such as AMPA potentiators, potassium channel openers, antiproliferatives and Alzheimer’s progression will be discussed.

3:00 The Imaging Probe Development Center at NIH: Novel Imaging Agents for Biomedical R&D and Translational Medicine

Gary L. Griffiths, Ph.D., Director, Imaging Probe Development Center, National Heart, Lung, and Blood Institute, National Institutes of Health

Molecular imaging is a rapidly developing technology used for the study of biological processes at scales from the sub-cellular through animal and human systems, and relies largely on the use of target-specific molecular imaging probes in order to visualize these processes. Importantly, molecular imaging is playing an ever-increasing role in the clinical diagnoses of human diseases and in the development and application of new drugs intended for various disease treatments. The Imaging Probe Development Center (IPDC) was established under the original NIH Roadmap Initiative due to NIH's recognition of the need for probe supply in the further development of the field from basic through translational research. The IPDC supports research efforts across the broad spectrum of molecular imaging by providing molecular probes of any composition to its bioscientific collaborators. In this presentation, numerous examples of probes prepared at our Center will be presented along with relevant background discussions of their intended applications and these examples will encompass all imaging modalities, including optical, MRI, PET/SPECT, as well as multimodality agents.

3:30 Networking Refreshment Break, Poster and Exhibit Viewing

4:30 Novel PET Tracers as Translational Tools in Drug Discovery and Development

Dennis McCarthyDennis McCarthy, Ph.D., Director, Early Development, AstraZeneca R&D

Drug development is a time-consuming and costly endeavor. We now benefit from the discovery of new PET tracers that can be used to streamline this process. Their development requires a multidisciplinary approach combining the expertise of many fields. I will describe the discovery of new PET tracers and how, as translational tools, they can be used to expand our understanding of receptor biology and disease.

5:00 Panel Discussion with Afternoon Speakers

5:30 End of Day

Day 1  |  Day 2  |  Download Brochure